Patients with mild Alzheimer’s disease enrolled in the Phase III trials of the Alzheimer’s disease treatment tarenflurbil did not show better outcomes on measures of cognitive decline or loss of activities of daily life when compared to patients receiving a placebo.
These latest results for this Alzheimer’s disease treatment were recently reported in the Journal of the American Medical Association.
In exploring the theorized effects of an overproduction of amyloid-beta researchers hoped that tarenflurbil, a selective amyloid-beta lowering agent, as an Alzheimer’s disease treatment would be beneficial. Amyloid-beta is a peptide composed of certain amino acids that appear in brain plaques of patients with Alzheimer’s and it is thought to contribute to the onset of the brain disease.
In performing its Phase III trials on this Alzheimer’s treatment researcher was conducted at 133 research sites and involved 1,684 participants. Patients were randomized to receive the Alzheimer’s disease treatment consisting of 800mg tarenflurbil or a placebo. A total of 1,046 Alzheimer’s patients completed the 18-month trial.
Researchers concluded that the Alzhiemer’s treatment had no beneficial effect on the primary outcomes of cognition and activities of living after the 18-month trial. In examining secondary outcomes such as quality of life and caregiver burden, this Alzheimer’s disease treatment showed no significant differences in those outcomes.
While participating in the trials, patients receiving the Alzheimer’s treatment tarenflurbil showed more incidents of dizziness, upper respiratory tract infections and anemia than those taking the placebo.
These Phase III results of this Alzheimer’s disease treatment were somewhat surprising given the encouraging results shown from a Phase II trial.
Recent Comments